MBP431 (Mapp Biopharmaceutical)

MBP431 is an investigational pan-ebolavirus monoclonal antibody cocktail developed by Mapp Biopharmaceutical. It is a second-generation, half-life extended version of MBP134, consisting of two broadly neutralizing human monoclonal antibodies, ADI-15878YTE and ADI-23774YTE. These antibodies target highly conserved, non-overlapping epitopes on the ebolavirus glycoprotein (GP) and have been engineered with YTE mutations (M252Y/S254T/T256E) in their Fc regions to prolong serum half-life and enable intramuscular (IM) administration. MBP431 is designed for post-exposure prophylaxis (PEP) and treatment of Ebola virus disease (EVD) caused by multiple ebolavirus species, including Zaire ebolavirus (EBOV), Sudan ebolavirus (SUDV), and Bundibugyo ebolavirus (BDBV). Preclinical studies in non-human primates have demonstrated that a single IM dose of MBP431 provides significant protection against lethal ebolavirus challenges, and its combination with the antiviral remdesivir further enhances survival outcomes in advanced stages of disease.

Other names

ADI-15878YTE + ADI-23774YTEADI-15878YTE and ADI-23774YTEADI15878YTE and ADI-23774YTEADI 15878YTE and ADI-23774YTE